ATE425253T1 - Tribonektine - Google Patents

Tribonektine

Info

Publication number
ATE425253T1
ATE425253T1 AT00926303T AT00926303T ATE425253T1 AT E425253 T1 ATE425253 T1 AT E425253T1 AT 00926303 T AT00926303 T AT 00926303T AT 00926303 T AT00926303 T AT 00926303T AT E425253 T1 ATE425253 T1 AT E425253T1
Authority
AT
Austria
Prior art keywords
tribonectins
tribosupplementation
tribonectin
injured
administering
Prior art date
Application number
AT00926303T
Other languages
English (en)
Inventor
Gregory Jay
Original Assignee
Rhode Island Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23152784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE425253(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhode Island Hospital filed Critical Rhode Island Hospital
Application granted granted Critical
Publication of ATE425253T1 publication Critical patent/ATE425253T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Conductive Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00926303T 1999-04-23 2000-04-24 Tribonektine ATE425253T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/298,970 US6743774B1 (en) 1999-04-23 1999-04-23 Tribonectins

Publications (1)

Publication Number Publication Date
ATE425253T1 true ATE425253T1 (de) 2009-03-15

Family

ID=23152784

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00926303T ATE425253T1 (de) 1999-04-23 2000-04-24 Tribonektine

Country Status (9)

Country Link
US (6) US6743774B1 (de)
EP (1) EP1173567B2 (de)
JP (5) JP2003500022A (de)
AT (1) ATE425253T1 (de)
AU (1) AU781564B2 (de)
CA (1) CA2367750C (de)
DE (1) DE60041761D1 (de)
ES (1) ES2324199T5 (de)
WO (1) WO2000064930A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743774B1 (en) * 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
GB0003092D0 (en) 2000-02-10 2000-03-29 Glaxo Group Ltd Superficial zone protein-binding molecules and uses thereof
WO2001058958A1 (en) * 2000-02-09 2001-08-16 Glaxo Group Limited Antibody binding superficial zone protein and their uses in diagnosis and screening methods
EP1347993A2 (de) * 2000-12-29 2003-10-01 Glaxo Group Limited Das "superficial zone protein" und verfahren zu dessen herstellung und anwendung
EP1401481A1 (de) * 2001-06-14 2004-03-31 Novo Nordisk A/S Schleimhautreparatur mit tff-dimer-peptiden
US20060240037A1 (en) * 2003-06-04 2006-10-26 Edward Fey Methods and compositions for the treatment and prevention of degenerative joint disorders
UA91818C2 (ru) * 2003-08-14 2010-09-10 Уайт Рекомбинантные молекулы лубрицина и их использование
WO2005102363A2 (en) * 2004-04-20 2005-11-03 Mucosal Therapeutics Llc Methods of promoting cartilage healing or cartilage integration
WO2006012492A2 (en) * 2004-07-23 2006-02-02 Mucosal Therapeutics Llc Compositions and methods for viscosupplementation
US20080139458A1 (en) * 2004-12-03 2008-06-12 Jay Gregory D Methods of Treatment For Injured or Diseased Joints
US20070111327A1 (en) * 2005-05-05 2007-05-17 Jay Gregory D Methods of detecting lubricin
US20090298761A1 (en) * 2006-05-17 2009-12-03 Donald Engelman Methods of treating cartilage defects using a soluble morphogenic protein complex
US20090068247A1 (en) * 2007-09-12 2009-03-12 Mucosal Therapeutics Biocompatible devices coated with a tribonectin and methods for their production
US20090104148A1 (en) * 2007-09-18 2009-04-23 Jay Gregory D Treatment and prevention of joint disease
EP2915529B1 (de) 2008-05-07 2017-06-14 The Regents of The University of California Therapeutische Auffüllung und Anreicherung der Augenflächenbenetzung
ES2534082T3 (es) 2009-01-13 2015-04-17 Lubris Llc Modulación terapéutica de la lubricación del límite del epitelio vaginal
WO2010087521A1 (ja) * 2009-01-29 2010-08-05 独立行政法人理化学研究所 関節疾患治療用の組み合わせ製剤
CA2762989C (en) 2009-05-22 2021-04-13 Benjamin Sullivan Prg4 for treatment of oral cavity boundary lubrication disorders
EP2525805B1 (de) 2010-01-19 2017-03-15 Lubris LLC Mundpflegezusammensetzungen und -verfahren
US8716204B2 (en) 2010-07-27 2014-05-06 Zimmer, Inc. Synthetic synovial fluid compositions and methods for making the same
US20130116186A1 (en) * 2011-10-04 2013-05-09 Rhode Island Hospital, A Lifespan Partner Lubricin injections to maintain cartilage health
DK2948553T3 (da) * 2013-01-25 2020-06-29 Baylor College Medicine Hjælper-afhængigt afgivelses- og ekspressionssystem til adenoviral genterapi
US9982027B2 (en) 2013-10-22 2018-05-29 Lubris Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
EP3074022B1 (de) 2013-11-26 2022-03-30 Lubris LLC Zusammensetzungen und verfahren zur verhinderung interzellulärer interaktionen
EA036291B1 (ru) 2015-01-26 2020-10-22 ЛУБРИС ЭлЭлСи Применение prg4 в качестве противовоспалительного средства
WO2016187414A1 (en) 2015-05-19 2016-11-24 Lubris Llc Use of prg4 to improve dynamic visual acuity and higher order aberrations
WO2017123934A1 (en) * 2016-01-13 2017-07-20 Merial, Inc. Recombinant aav vectors expressing osteoprotective genes, including has2 and lubricin, useful in the treatment of osteoarthritis and related joint conditions in mammals
EP3420354A1 (de) 2016-02-23 2019-01-02 Lynxon AB Verfahren zur diagnose von arthritis oder anderen gelenksabbauenden krankheiten
KR20220145361A (ko) 2020-02-24 2022-10-28 노파르티스 아게 재조합적으로 생성된 폴리펩타이드의 정제
JP7063369B2 (ja) * 2020-12-07 2022-05-09 株式会社三洋物産 遊技機
US20250282981A1 (en) 2022-04-27 2025-09-11 Lubris Llc Methods of making polymer films

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2734862A (en) 1956-02-14 Synthetic casein fiber elastic grease
US2487377A (en) 1948-04-17 1949-11-08 Socony Vacuum Oil Co Inc Lubricant
US2878184A (en) 1953-12-29 1959-03-17 Rockwell Mfg Co Hydrocarbon resistant glycerol base lubricant
AR207237A1 (es) 1974-02-25 1976-09-22 Thomas A Procedimiento para obtener extractos biologicos estables liofilizados solubles constituidos por complejos proteicos termorresistentes
EP0050644B1 (de) 1980-04-25 1985-09-18 A/S Orthana Kemisk Fabrik Sterilisierte, konservierte, stabile, mucin enthaltende lösungen und sterilisationsverfahren
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US5403592A (en) * 1987-08-25 1995-04-04 Macnaught Pty Limited Lubricant composition for rheumatism
GB8803697D0 (en) 1988-02-17 1988-03-16 Deltanine Research Ltd Clinical developments using amniotic membrane cells
US5510418A (en) 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5260417A (en) 1989-04-03 1993-11-09 Genetics Institute, Inc. Megakaryocyte growth promoting activity protein
US5326558A (en) 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
US6433142B1 (en) * 1989-08-08 2002-08-13 Genetics Institute, Llc Megakaryocyte stimulating factors
CA2060223C (en) 1991-02-12 1999-07-20 Clarence C. Lee Injectable medical lubricating fluid composition and method of use
JPH04278061A (ja) 1991-03-05 1992-10-02 Suntory Ltd 栄養食品
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US5709020A (en) 1994-07-19 1998-01-20 University Of Kentucky Research Foundation Method for reducing the generation of wear particulates from an implant
US5515590A (en) 1994-07-19 1996-05-14 University Of Kentucky Research Foundation Method for reducing the generation of wear particulates from an implant
US5510122A (en) 1994-09-28 1996-04-23 The Research Foundation Of State University Of New York Preparation and use of whole saliva
FR2726188B1 (fr) * 1994-11-02 1996-12-20 Inst Vaisseaux Et Du Sang Composition glycosaminoglycane/facteur de croissance megacaryocytaire, utilisation en therapeutique
US5639734A (en) * 1994-12-20 1997-06-17 Esko; Jeffrey D. Disaccharide inflammation inhibitors and uses thereof
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
AT405477B (de) * 1996-04-03 1999-08-25 Norbert Mag Fuchs Kombinationspräparat
WO1998018491A1 (en) 1996-10-28 1998-05-07 BURGSTINER, Jacqueline, Cook Methods and compositions for dietary supplementation
US6743774B1 (en) 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
US6960562B2 (en) * 1999-04-23 2005-11-01 Rhode Island Hospital, A Lifespan Partner Tribonectin polypeptides and uses thereof
US7001881B1 (en) * 1999-04-23 2006-02-21 Rhode Island Hospital Tribonectins
JP2004517030A (ja) * 1999-05-24 2004-06-10 アバロン バイオサイエンシーズ， インコーポレイテッド グリコシルトランスフェラーゼインヒビター
WO2001007068A1 (en) * 1999-07-23 2001-02-01 Case Western Reserve University Novel methods and reagents for the treatment of osteoarthritis
US6291533B1 (en) * 1999-12-22 2001-09-18 Vitamerica, Inc. Dietary supplements for each specific blood type
GB0003092D0 (en) * 2000-02-10 2000-03-29 Glaxo Group Ltd Superficial zone protein-binding molecules and uses thereof
EP1347993A2 (de) * 2000-12-29 2003-10-01 Glaxo Group Limited Das "superficial zone protein" und verfahren zu dessen herstellung und anwendung
GB2394419B (en) 2001-06-25 2005-09-07 Inspire Pharmaceuticals Inc Joint lubrication with p2y purinergic receptor agonists
GB2381750A (en) * 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
US20030224386A1 (en) * 2001-12-19 2003-12-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
UA91818C2 (ru) 2003-08-14 2010-09-10 Уайт Рекомбинантные молекулы лубрицина и их использование
WO2005084684A1 (de) 2004-03-05 2005-09-15 Synthes Ag Chur Verwendung eines gemisches für die herstellung eines mittels zur behandlung von defektem oder degeneriertem knorpel in vivo und bei der herstellung von natürlichem knorpelerszy in vitro
WO2006012492A2 (en) * 2004-07-23 2006-02-02 Mucosal Therapeutics Llc Compositions and methods for viscosupplementation
US20070111327A1 (en) * 2005-05-05 2007-05-17 Jay Gregory D Methods of detecting lubricin

Also Published As

Publication number Publication date
JP5909592B2 (ja) 2016-04-26
US7618941B2 (en) 2009-11-17
EP1173567B2 (de) 2012-10-31
JP2012070738A (ja) 2012-04-12
WO2000064930A2 (en) 2000-11-02
AU781564B2 (en) 2005-06-02
US8026346B2 (en) 2011-09-27
EP1173567B1 (de) 2009-03-11
US20100204087A1 (en) 2010-08-12
JP2003500022A (ja) 2003-01-07
US20040229804A1 (en) 2004-11-18
US20100048458A1 (en) 2010-02-25
US8680057B2 (en) 2014-03-25
JP2016041769A (ja) 2016-03-31
EP1173567A2 (de) 2002-01-23
WO2000064930A3 (en) 2001-01-25
ES2324199T3 (es) 2009-08-03
ES2324199T5 (es) 2013-03-20
DE60041761D1 (de) 2009-04-23
US20140179611A1 (en) 2014-06-26
CA2367750C (en) 2013-10-22
US6743774B1 (en) 2004-06-01
JP2014144015A (ja) 2014-08-14
US20130072435A1 (en) 2013-03-21
JP2016172760A (ja) 2016-09-29
CA2367750A1 (en) 2000-11-02
AU4485200A (en) 2000-11-10

Similar Documents

Publication Publication Date Title
DE60041761D1 (de) Tribonektine
DE69907977D1 (de) Pyrrolobenzodiazepine
ATE264863T1 (de) 28-epirapaloge
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
NO974554L (no) FremgangsmÕte for behandling av en underjordisk formasjon
DE69929418D1 (de) Implantierbare medizinische vorrichtung
DK1303632T3 (da) Galactomannan-oligosaccharid og fremgangsmåde til fremstilling samt anvendelse heraf
DE59807369D1 (de) Medizinische Bandage
PT797439E (pt) Utilizacao de pramipexote como agente neuroprotector
PT998287E (pt) Utilizacao de levobupivacaina
IT1285770B1 (it) Composti corticoidei
EA200200742A1 (ru) 1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии
ATE202483T1 (de) Immuntolerante prothrombinkomplex-präparation
SE9801494D0 (sv) Novel use
IS6087A (is) N-(2-fenýl-4-amínó-bútýl)-1-naftamíð sem virka á móti taugakínín-1 viðtaka
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
AR022321A1 (es) Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada
EA200100930A1 (ru) Способ лечения хозл
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
BG100248A (bg) Инхибитори на скваленсинтетаза
EA200101106A1 (ru) Фармацевтический комплекс
NO20005548L (no) Mykobakterieinhibitorer
HRP20050611A2 (en) Combination medicament

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties